[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)
Conditions
- Metastatic Prostate Cancer
- Prostate Cancer
Interventions
- DRUG: 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one
- DEVICE: FTT-PET/CT
- DIAGNOSTIC_TEST: EnhanceAR-Seq
Sponsor
Washington University School of Medicine
Collaborators